upton
allen
mbb
msc
frcpc
b
c
michael
green
md
mph
e
organ
transplant
practic
mean
rehabilit
patient
varieti
form
end
organ
dysfunct
procedur
arguabl
outstand
clinic
biomed
accomplish
last
decad
potent
immunosuppress
drug
dramat
reduc
incid
reject
transplant
organ
also
increas
suscept
patient
opportunist
infect
thu
success
organ
transplant
depend
part
effect
prevent
diagnosi
treatment
infecti
diseas
transplant
end
emphasi
increasingli
place
prevent
transplant
patient
evid
microbi
invas
first
year
transplant
effect
microbi
invas
divers
result
direct
indirect
consequ
direct
consequ
result
varieti
clinic
infecti
diseas
syndrom
mononucleosi
pneumonia
gastroenter
hepat
among
entiti
indirect
consequ
mediat
cytokin
chemokin
growth
factor
elabor
transplant
recipi
respons
microbi
replic
invas
contribut
net
state
immunosuppress
pathogenesi
acut
chronic
allograft
injuri
case
develop
lymphoprolif
malign
disord
risk
infect
solid
organ
transplant
patient
larg
determin
interact
factor
technicalanatom
factor
involv
transplant
procedur
periop
aspect
care
manag
vascular
access
drain
endotrach
tube
environment
exposur
box
patient
net
state
immunosuppress
box
case
technicalanatom
mishap
best
way
prevent
infect
correct
anatom
abnorm
coverag
appropri
antimicrobi
therapi
antimicrobi
treatment
alon
elimin
risk
develop
recurr
infect
relat
uncorrect
problem
consequ
transplant
recipi
remain
high
risk
subsequ
infect
increas
risk
develop
antimicrobi
resist
success
correct
underli
abnorm
one
consid
therapi
transplant
patient
concept
therapeut
prescript
packag
use
packag
major
compon
immunosuppress
compon
prevent
treat
reject
antimicrobi
compon
make
safe
thu
natur
antimicrobi
program
administ
must
close
link
natur
intens
immunosuppress
program
requir
result
net
state
immunosuppress
mode
antimicrobi
agent
administ
transplant
recipi
therapeut
mode
antimicrobi
agent
administ
treatment
establish
clinic
infect
prophylact
mode
antimicrobi
agent
administ
entir
popul
event
prevent
occurr
infect
import
enough
justifi
intervent
preemptiv
mode
antimicrobi
agent
administ
subpopul
note
particular
risk
clinic
import
infect
base
clinic
epidemiolog
laboratori
marker
review
focu
prevent
strategi
prophylact
preemptiv
diagnosi
manag
establish
infect
infect
posttranspl
period
stereotyp
tempor
pattern
timet
although
clinic
syndrom
pneumonia
occur
time
point
transplant
caus
may
differ
differ
time
point
fig
delin
timet
onset
infect
organ
transplant
absenc
effect
prevent
strategi
prevent
antimicrobi
therapi
fail
complet
protect
patient
common
clinic
effect
extend
time
period
infecti
complic
like
appear
exampl
case
cytomegaloviru
cmv
infect
absenc
prophylaxi
cmvinduc
clinic
diseas
common
month
transplant
prophylaxi
use
fail
common
diseas
occur
month
transplant
depend
natur
durat
prophylaxi
immunosuppress
regimen
like
patient
transplant
recipi
risk
acquir
infect
health
care
commun
set
infect
necessarili
transplant
specif
fig
graphic
represent
time
infect
posttranspl
period
gener
time
period
recogn
differ
form
infect
first
month
major
caus
infect
infect
present
recipi
transplant
effect
increas
result
surgeri
anesthesia
immunosuppress
therapi
infect
convey
contamin
allograft
bacteri
candid
infect
wound
lung
drainag
cathet
vascular
access
devic
seen
nonimmunosuppress
patient
undergo
compar
surgeri
infect
occur
first
month
transplant
fall
last
categori
main
factor
determin
incid
infect
technic
aspect
surgeri
well
specif
aspect
periop
postop
care
second
time
period
effect
immun
suppress
notabl
risk
infect
period
major
class
infect
predomin
first
attribut
group
viral
pathogen
associ
latent
andor
chronic
infect
exampl
includ
cmv
epsteinbarr
viru
ebv
human
herp
viru
hepat
virus
b
c
may
caus
diseas
acquisit
primari
infect
typic
donor
secondari
infect
within
recipi
pressur
immun
suppress
secondari
infect
includ
reactiv
latent
pathogen
reinfect
new
strain
second
set
pathogen
observ
time
period
caus
socal
opportunist
infect
includ
organ
listeria
monocytogen
aspergillu
fumigatu
pneumocysti
jiroveci
develop
infect
opportunist
pathogen
attribut
combin
sustain
immunosuppress
often
combin
immunomodul
effect
viral
infect
creat
net
state
immunosuppress
great
enough
opportunist
infect
occur
without
especi
intens
environment
exposur
inform
describ
infect
occur
children
month
transplant
limit
transplant
recipi
commonli
return
home
often
far
transplant
center
accordingli
detail
regard
infecti
complic
occur
time
period
may
bias
includ
signific
infect
result
hospit
despit
limit
experi
support
divid
individu
infect
last
time
period
main
categori
patient
good
result
transplant
mainten
immunosuppress
good
allograft
function
greatest
risk
typic
communityacquir
infect
influenza
parainfluenza
respiratori
syncyti
viru
smaller
group
patient
poorer
outcom
transplant
excess
acut
chronic
immunosuppress
poor
allograft
function
often
chronic
viral
infect
patient
remain
high
risk
recurr
infect
relat
uncorrect
mechan
problem
well
opportunist
infect
attribut
organ
like
pneumocysti
jiroveci
listeria
monocytogen
cryptococcu
neoforman
nocardia
asteroid
time
line
infect
transplant
outlin
wide
spectrum
infect
occur
transplant
among
infect
major
burden
repres
bacteria
candida
speci
cmv
ebv
adenoviru
varicella
zoster
viru
communityacquir
respiratori
virus
addit
certain
infect
repres
challeng
specif
organ
group
eg
bk
viru
infect
renal
transplant
recipi
toxoplasma
infect
heartheartlung
transplant
recipi
select
aspect
infect
summar
later
indic
earlier
bacteri
infect
commonli
seen
earli
posttranspl
period
howev
bacteri
infect
occur
time
transplant
risk
factor
includ
presenc
indwel
cathet
devic
includ
endotrach
tube
foley
cathet
central
venou
cathet
regard
hospitalacquir
gramneg
organ
coagulaseneg
staphylococci
staphylococcu
aureu
often
encount
natur
infect
specif
pathogen
involv
vari
accord
organ
transplant
site
infect
microbiolog
flora
institut
pretranspl
statu
patient
gener
common
site
bacteri
infect
near
site
transplant
urinari
tract
infect
notabl
pyelonephr
recogn
common
infecti
complic
among
renal
transplant
recipi
infect
organ
transplant
liver
transplant
recipi
frequent
site
bacteri
infect
within
intraabdomin
space
often
accompani
bacteremia
intraabdomin
wound
infect
also
commonli
seen
intestin
transplant
recipi
bacteremia
partli
explain
disrupt
mucos
barrier
associ
harvest
injuri
reject
commonli
seen
infect
lower
respiratori
tract
includ
pneumonia
lung
abscess
common
site
infect
report
seri
pediatr
heart
transplant
recipi
mediastin
anoth
import
infect
thorac
transplant
particularli
reexplor
chest
requir
pathogen
associ
mediastin
includ
aureu
gramneg
enter
bacilli
children
undergo
lung
transplant
cystic
fibrosi
experi
high
rate
infecti
complic
often
preexist
colon
resist
organ
includ
pseudomona
speci
burkholderia
speci
bacteri
pathogen
given
import
difficulti
treat
often
resist
organ
transplant
center
usual
recommend
thorough
microbiolog
evalu
heartlung
lung
transplant
candid
transplant
transplant
patient
also
risk
develop
infect
result
communityacquir
bacteri
pathogen
import
streptococcu
pneumonia
pneumococcu
transplant
recipi
known
increas
risk
pneumococc
sepsi
among
patient
heart
recipi
transplant
young
age
seem
increas
risk
compar
pediatr
organ
recipi
frequenc
fungal
infect
vari
accord
type
organ
transplant
exampl
invas
fungal
infect
uncommon
renal
transplant
patient
frequent
encount
entiti
candida
urinari
tract
infect
similarli
liver
heart
intestin
transplant
recipi
major
fungal
infect
also
caus
candida
speci
patient
invas
aspergillosi
mycos
occur
uncommonli
consequ
invas
aspergillosi
noncandid
mycos
associ
invas
infect
frequent
devast
lung
transplant
recipi
uniqu
experi
proportion
infect
aspergillu
speci
compar
organ
recipi
infect
often
seen
children
undergo
transplant
treatment
cystic
fibrosi
reflect
infect
aspergillu
present
recipi
transplant
howev
aspergillu
also
frequent
recov
lung
transplant
recipi
oblit
bronchiol
chronic
reject
lung
regardless
caus
origin
lung
diseas
lead
transplant
cmv
cmv
infect
diseas
remain
import
caus
mortal
morbid
among
pediatr
organ
transplant
recipi
data
precis
burden
pediatr
organ
transplant
recipi
limit
howev
wide
differ
data
collect
report
addit
nonuniform
approach
laboratori
diagnosi
definit
cmv
diseas
appli
retrospect
studi
affect
abil
interpret
avail
data
center
unit
state
liver
transplant
patient
experienc
cmv
diseas
within
year
transplant
review
firsttim
pediatr
lung
transplant
patient
indic
among
atrisk
subject
incid
cmv
viremia
wherea
incid
cmv
pneumon
first
year
transplant
cmv
diseas
often
associ
fever
hematolog
abnorm
includ
leucopenia
atyp
lymphocytosi
thrombocytopenia
viscer
site
affect
may
includ
gastrointestin
tract
lung
liver
central
nervou
system
involv
includ
chorioretin
rare
organ
transplant
recipi
diagnosi
cmv
infect
diseas
organ
transplant
recipi
affect
variabl
lack
sensit
andor
specif
differ
diagnost
test
serolog
role
diagnosi
activ
cmv
diseas
transplant
differenti
prior
infect
activ
diseas
interpret
serolog
result
confus
potenti
presenc
passiv
antibodi
blood
product
provid
transplant
procedur
addit
alter
immun
respons
transplant
might
impair
patient
abil
mount
predict
humor
respons
viral
cultur
blood
cmv
limit
clinic
use
diagnosi
diseas
caus
poor
sensit
role
cmv
urin
cultur
diagnosi
diseas
caus
poor
specif
posit
cultur
bronchoalveolar
lavag
specimen
may
correl
diseas
presenc
posit
measur
cmv
load
peripher
blood
measur
either
nucleic
acid
amplif
techniqu
nat
antigenemia
assay
patient
compat
cmv
clinic
syndrom
strongli
suggest
cmv
diseas
howev
cmv
load
may
posit
onset
absenc
clinic
diseas
may
seen
presenc
diseas
caus
cmv
load
peripher
blood
may
neg
patient
tissu
invas
diseas
especi
cmv
involv
gastrointestin
tract
given
variabl
use
test
histopatholog
examin
involv
organ
essenti
confirm
presenc
cmv
diagnosi
invas
cmv
diseas
consid
intraven
ganciclovir
mgkgd
given
twice
daili
remain
prefer
drug
treatment
cmv
diseas
pediatr
transplant
recipi
reduct
immunosuppress
desir
unless
concurr
evid
reject
preclud
ganciclovir
therapi
sometim
accompani
cmv
hyperimmun
globulin
therapi
center
typic
clinic
respons
treatment
expect
day
treatment
initi
foscarnet
cidofovir
may
consid
set
ganciclovir
resist
optim
length
treatment
determin
monitor
viral
load
weekli
treatment
typic
continu
consecut
neg
sampl
obtain
case
seriou
diseas
tissu
invas
diseas
without
viremia
longer
treatment
period
clinic
monitor
specif
diseas
manifest
recommend
data
emerg
use
valganciclovir
prevent
treatment
cmv
infectiondiseas
among
adult
transplant
recipi
consider
less
data
avail
children
summari
approach
prophylaxi
outlin
tabl
includ
role
ganciclovir
without
immun
globulin
suggest
durat
use
indic
although
fear
ebvassoci
diseas
transplant
posttranspl
lymphoprolif
disord
ptld
patient
may
experi
broad
rang
clinic
symptom
meet
definit
ptld
might
includ
manifest
infecti
mononucleosi
fever
malais
exud
pharyng
lymphadenopathi
hepatosplenomegali
atyp
lymphocytosi
specif
organ
diseas
hepat
pneumon
gastrointestin
symptom
hematolog
manifest
leucopenia
thrombocytopenia
hemolyt
anemia
haemophagocytosi
ebvassoci
leiomyosarcoma
also
describ
ebv
diseas
seen
frequent
patient
experienc
primari
ebv
infect
follow
transplant
rate
ebv
diseas
ptld
vari
accord
organ
transplant
recipi
intestin
lung
highest
risk
receiv
liver
kidney
heart
lower
risk
cmv
diseas
serolog
use
diagnosi
posttranspl
period
presenc
increas
ebv
viral
load
peripher
blood
determin
quantit
polymeras
chain
reaction
pcr
wide
accept
assay
predict
indic
like
presenc
ptld
howev
assay
limit
specif
may
remain
persist
elev
asymptomat
patient
definit
diagnosi
ebv
diseas
includ
ptld
requir
histopatholog
examin
biopsi
materi
use
ebvspecif
assay
eg
ebv
encod
rna
eber
stain
enhanc
sensit
specif
histolog
examin
patient
approach
treatment
ebv
diseas
ptld
remain
somewhat
controversi
reduct
immun
suppress
wide
accept
critic
manag
patient
complic
role
antivir
agent
acyclovir
ganciclovir
unproven
although
mani
transplant
clinician
use
treatment
ebv
infect
treatment
approach
often
modifi
regimen
use
treat
cmv
diseas
current
antivir
agent
use
treat
ebv
agent
choic
ganciclovir
vitro
time
activ
ebv
compar
acyclovir
controversi
use
agent
ebvptld
aris
although
agent
suppress
ebv
lytic
infect
infect
organ
transplant
seem
limit
valu
treatment
nonlyt
ebv
prolifer
believ
domin
compon
ebvrel
ptld
increas
evid
albeit
anecdot
support
use
monoclon
rituximab
treatment
ebv
diseas
ptld
howev
optim
time
treatment
strategi
agent
remain
defin
addit
altern
strategi
use
chemotherapi
requir
collabor
input
oncologist
familiar
manag
ebvrel
diseas
organ
transplant
recipi
prevent
posttranspl
ebv
diseas
includ
ptld
remain
controversi
antivir
regimen
model
cmv
scenario
date
preemptiv
reduct
immunosuppress
set
increas
viral
load
may
support
data
increasingli
use
see
tabl
adenoviru
infect
may
acquir
exogen
mean
endogen
result
reactiv
latent
infect
clinic
spectrum
infect
diseas
pediatr
transplant
recipi
variabl
serotyp
gener
show
fidel
relat
type
organ
affect
result
syndrom
among
liver
transplant
patient
diseas
manifest
includ
selflimit
fever
gastroenter
cystiti
hepat
pneumon
manifest
may
occur
transplant
recipi
depend
level
immunosuppress
adenoviru
dna
detect
peripher
blood
use
qualit
quantit
pcr
techniqu
appropri
clinic
set
presenc
adenoviru
dna
blood
provid
presumpt
evid
infect
examin
tissu
histopatholog
provid
definit
evid
infect
manag
adenoviru
infect
pose
challeng
limit
effect
treatment
option
cidofovir
current
accept
drug
choic
howev
conclus
primarili
base
retrospect
review
histor
experi
agent
approv
indic
us
food
drug
administr
similar
agenc
nonetheless
ongo
experi
continu
support
role
treatment
adenovir
infect
agent
advent
cidofovir
intraven
ribavirin
use
anecdot
report
success
failur
although
major
burden
bk
viru
infect
among
adult
renal
transplant
patient
role
viru
pediatr
organ
transplant
becom
clearli
defin
infect
result
reactiv
adult
primari
infect
may
occur
notabl
among
pediatr
transplant
recipi
major
clinic
manifest
renal
transplant
recipi
tubulointerstiti
nephriti
renal
biopsi
requir
definit
diagnosi
noninvas
test
modal
includ
screen
blood
urin
bk
dna
use
pcr
firm
consensu
prefer
approach
manag
bk
nephropathi
earli
detect
desir
goal
end
quantit
pcr
monitor
bk
dna
perform
center
often
provid
opportun
modul
immunosuppress
situat
antivir
therapi
use
agent
often
use
cidofovir
report
success
howev
present
consensu
exist
support
therapeut
efficaci
agent
varicella
zoster
viru
vzv
major
threat
pediatr
transplant
patient
mani
individu
enter
transplant
without
immun
viru
immunosuppress
individu
risk
sever
outcom
vzv
infect
viscer
involv
may
accompani
sever
infect
clinician
remind
dissemin
diseas
rare
occur
absenc
typic
cutan
vesicl
pretranspl
vaccin
shown
provid
sustain
humor
immun
least
year
transplant
strongli
recommend
transplant
candid
vaccin
transplant
given
live
vaccin
minimum
interv
vaccin
transplant
recommend
week
although
center
select
consid
use
vzv
vaccin
suscept
children
transplant
approach
recommend
time
lack
safeti
data
given
known
risk
live
vaccin
immunosuppress
individu
famili
transplant
patient
educ
alert
potenti
exposur
set
school
report
promptli
health
care
provid
allow
postexposur
prophylaxi
varicellasuscept
transplant
recipi
receiv
varicella
zoster
immun
globulin
within
hour
varicella
exposur
window
pass
varicella
zoster
immun
globulin
avail
option
use
postexposur
chemoprophylaxi
acyclovir
mgkgd
given
time
daili
day
maximum
dose
mg
time
daili
start
day
exposur
absenc
profound
immunosuppress
prophylaxi
usual
necessari
expos
organ
recipi
immun
vzv
result
prior
infect
vaccin
transplant
treatment
transplant
patient
vzv
infect
usual
initi
intraven
acyclovir
evid
clinic
improv
fever
abat
new
lesion
lesion
start
crust
viscer
diseas
outpati
treatment
oral
acyclovir
valacyclovir
use
children
mild
infect
low
level
immunosuppress
concern
regard
adequaci
followup
famciclovir
valacyclovir
approv
use
adult
famciclovir
prodrug
penciclovir
extend
halflif
infect
cell
valayclovir
prodrug
acyclovir
produc
fourfold
greater
serum
level
produc
acyclovir
pediatr
formul
current
avail
children
undergon
organ
transplant
experi
communityacquir
viral
infect
signific
problem
howev
well
recogn
children
significantli
immunocompromis
sever
diseas
caus
virus
includ
respiratori
syncyti
viru
infect
parainfluenza
influenza
virus
pediatr
transplant
recipi
likelihood
sever
outcom
greater
earli
month
transplant
period
peak
immunosuppress
advent
pandem
strain
influenza
pandem
caus
concern
gener
principl
govern
prevent
treatment
pandem
pediatr
transplant
patient
similar
season
influenza
transplant
patient
among
known
increas
risk
sever
outcom
pandem
candid
treatment
oseltamivir
zanamivir
appropri
acut
respiratori
ill
suspect
confirm
caus
like
immunocompromis
patient
increas
risk
prolong
shed
viru
harbor
drugresist
strain
influenza
includ
pandem
pediatr
transplant
patient
candid
vaccin
viru
season
influenza
greater
month
age
infect
organ
transplant
expert
current
delay
vaccin
first
month
follow
organ
transplant
pneumocysti
pneumonia
pcp
recogn
threat
posttranspl
period
risk
greatest
first
month
transplant
time
onset
usual
first
month
trimethoprimsulfamethoxazol
remain
prophylact
agent
choic
agent
also
prefer
initi
therapi
individu
develop
pcp
although
optim
durat
pcp
prophylaxi
remain
unclear
expert
provid
pcp
prophylaxi
minimum
month
recommend
indefinit
use
especi
solid
organ
transplant
recipi
requir
prolong
period
higher
level
immunosuppress
intraven
pentamidin
altern
treatment
pcp
patient
intoler
trimethoprimsulfamethoxazol
whose
diseas
respond
agent
day
howev
pentamidin
associ
rel
high
incid
advers
event
includ
pancreat
renal
dysfunct
hypoglycemia
hyperglycemia
atovaquon
may
use
treat
milder
form
pcp
among
adult
howev
pediatr
data
limit
altern
trimethoprimsulfamethoxazol
prophylaxi
includ
oral
atovaquon
dapson
aerosol
pentamidin
recommend
children
toler
oral
agent
anoth
altern
intraven
pentamidin
albeit
risk
greater
toxic
toxoplasma
gondii
infect
greatest
concern
among
heart
transplant
patient
infect
occur
categori
transplant
recipi
includ
kidney
liver
recipi
toxoplasma
organ
remain
encyst
within
muscl
tissu
cardiac
muscl
thu
infect
acquir
result
reactiv
cyst
remain
dormant
donor
heart
toxoplasma
seroneg
children
clinic
manifest
occur
earli
week
transplant
manifest
includ
pneumonia
fever
syndrom
myocard
chorioretin
central
nervou
system
diseas
current
prophylaxi
includ
pyrimethaminesulfadiazin
patient
trimethoprimsulfamethoxazol
typic
use
patient
howev
expert
also
recommend
trimethoprimsulfamethoxazol
patient
durat
prophylaxi
usual
month
infect
parasit
worm
relev
individu
previous
acquir
infect
follow
period
resid
endem
region
donorassoci
transmiss
stronygloid
also
occur
asymptomat
immunocompromis
person
includ
transplant
recipi
risk
strongyloid
hyperinfect
result
dissemin
larva
via
system
circul
result
abdomin
pain
diffus
pulmonari
infiltr
septicemia
mening
enter
gramneg
bacilli
serolog
screen
recommend
individu
endem
region
tabl
ivermectin
treatment
indic
screenposit
individu
tuberculosi
tb
alway
concern
immunocompromis
host
incid
rate
low
transplant
center
develop
world
outcom
tb
devast
organ
transplant
recipi
transplant
care
histori
tb
exposur
infect
mantoux
test
screen
chest
radiograph
assist
establish
diagnosi
latent
tuberculosi
infect
interferongamma
releas
assay
current
evalu
defin
role
set
tb
skin
test
poor
util
use
antitubercul
agent
transplant
patient
pose
challeng
interact
isoniazid
rifampin
immunosuppress
medic
howev
seen
contraind
use
antitubercul
agent
use
warrant
clinic
situat
pretranspl
phase
arguabl
import
phase
transplant
detail
histori
physic
examin
necessari
identifi
condit
influenc
risk
manag
infect
transplant
assess
allow
identif
preexist
condit
requir
treatment
prophylaxi
period
transplant
tabl
summar
screen
test
perform
pretranspl
period
immun
repres
import
strategi
prevent
infect
transplant
patient
wherev
possibl
vaccin
administ
pretranspl
period
improv
chanc
optim
immunolog
take
guidelin
vaccin
transplant
candidatepati
recent
publish
situat
acceler
vaccin
schedul
may
use
select
vaccin
given
differ
childhood
vaccin
schedul
differ
jurisdict
clinician
acquaint
appropri
schedul
circumst
acceler
schedul
could
use
use
vaccin
transplant
one
need
concern
safeti
well
efficaci
gener
live
viru
vaccin
avoid
transplant
recipi
oral
polio
yellow
fever
oral
typhoid
vaccin
live
contraind
immunosuppress
patient
live
attenu
intranas
influenza
vaccin
also
contraind
measl
mump
rubella
vaccin
somewhat
contraind
use
limit
outbreak
scenario
varicella
vaccin
also
somewhat
contraind
approv
use
transplant
patent
although
limit
publish
data
support
potenti
use
vaccin
transplant
recipi
expert
continu
advis
practic
case
nonliv
vaccin
major
concern
safeti
efficaci
thu
gener
advis
give
nonliv
vaccin
time
level
immunosuppress
would
allow
immunogen
tabl
summar
vaccin
indic
contraind
transplant
recipi
given
rel
burden
import
invas
pneumococc
diseas
pediatr
transplant
recipi
import
pneumococc
vaccin
underestim
donor
organ
screen
organ
donor
frequent
sourc
exposur
pathogen
organ
transplant
recipi
accordingli
screen
donor
organ
crucial
aspect
prevent
strategi
aim
minim
advers
outcom
infect
posttranspl
period
despit
longstand
recognit
import
donorderiv
infect
increas
concern
problem
emerg
recent
donorrel
transmiss
human
immunodefici
viru
hiv
case
well
concern
lack
sensit
serolog
test
rel
long
time
period
seroconvers
hiv
hepat
b
viru
hbv
hepat
c
viru
hcv
led
interest
use
natbas
test
pathogen
hiv
hcv
hbv
although
argument
exist
use
nat
test
final
intern
consensu
address
use
test
begin
emerg
decis
relat
use
test
must
consid
reliabl
technolog
also
feasibl
univers
implement
test
procedur
procur
organ
recent
case
donorassoci
transmiss
lymphocyt
choriomening
viru
west
nile
viru
also
rais
question
whether
panel
routin
test
perform
potenti
donor
expand
includ
potenti
donorderiv
pathogen
date
consensu
reach
whether
screen
pathogen
routin
includ
donor
test
panel
hope
implement
work
group
committe
focus
problem
donorderiv
infect
north
america
europ
lead
improv
data
better
inform
subsequ
recommend
regard
donor
test
current
requir
screen
nonliv
donor
shown
tabl
present
specif
requir
implement
screen
allen
green
live
donor
gener
test
strategi
place
deceas
donor
appli
use
organ
import
document
presenc
potenti
donortransmiss
pathogen
imper
inform
decis
make
regard
use
potenti
donor
organ
also
result
donor
test
inform
specif
prevent
strategi
even
donorassoci
exposur
pathogen
unavoid
variou
prophylaxi
regimen
use
posttranspl
period
although
common
basic
principl
specif
regimen
vari
across
center
type
organ
transplant
patient
major
target
prophylaxi
infect
organ
transplant
bacteri
pathogen
herp
group
virus
fungal
pathogen
includ
pneumocysti
periop
antibiot
typic
use
hour
provid
prophylaxi
surgic
contamin
burden
cmv
infect
transplant
patient
repres
major
focu
prevent
posttranspl
period
intraven
ganciclovir
usual
use
without
cmv
hyperimmun
globulin
select
patient
group
tabl
summar
variou
pathogen
regimen
often
use
prevent
infect
posttranspl
period
evalu
febril
transplant
patient
clinician
consid
child
fever
relat
common
childhood
infect
infect
uniqu
immunosuppress
transplant
recipi
end
time
infect
transplant
see
fig
provid
guidanc
regard
like
pathogen
exampl
discuss
earlier
like
caus
infect
within
first
month
transplant
often
bacteri
candid
larg
similar
seen
nonimmunosuppress
patient
undergon
compar
surgeri
natur
evalu
depend
clinic
statu
patient
whether
sourc
infect
identifi
examin
abnorm
focu
infect
defin
admiss
hospit
may
indic
depend
clinic
statu
patient
site
infect
diagnost
evalu
vari
includ
minimum
complet
blood
count
differenti
blood
urin
cultur
addit
investig
depend
clinic
assess
time
present
transplant
examin
normal
focu
infect
defin
patient
clinic
unwel
typic
requir
admiss
evalu
treatment
diagnost
evalu
consid
like
differenti
diagnos
consult
infecti
diseas
recommend
patient
well
may
necessarili
requir
admiss
howev
depend
sever
factor
includ
adequaci
followup
degre
immun
suppress
suspect
diagnos
diagnost
evalu
includ
minimum
complet
blood
count
differenti
blood
urin
cultur
situat
clinician
need
awar
spectrum
viral
infect
associ
febril
syndrom
without
necessarili
readili
appar
organ
focu
infect
eg
cmv
viru
